Here, Krisper and Stauber analyze the relative efficiency, clinical outcomes, safety and potential indications of two different 'liver dialysis' systems. Despite their 'experimental' status, the Molecular Adsorbents Recirculating System (MARS®) and Prometheus®, developed by Gambro and Fresenius Medical Care, respectively, are increasingly used to treat patients with severe hepatic failure. Preliminary data are promising, and large-scale randomized trials with the aim of proving a survival benefit are underway.
- Peter Krisper
- Rudolf E Stauber
